AdaptHealth Corp.

AdaptHealth Corp.(AHCO)股票分析

$6.390

+0.143 (+2.24%)收盘时

Loading chart…
最高
6.410
开盘
6.280
成交量加权均价
6.36
成交量
1.61M
市值
1.31B
最低
6.280
成交额
10.23M
企业价值/息税折旧摊销前利润(TTM)
6.25

AdaptHealth Corp. and subsidiaries are engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under three segments that align with its product categories: Sleep Health, Respiratory Health, and Wellness at Home. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea. The Respiratory Health segment provides oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services to individuals for the treatment of respiratory diseases, such as chronic obstructive pulmonary disease and chronic respiratory failure. The Wellness at Home segment provides home medical equipment and services to patients in their homes, including those who have been discharged from acute care and other facilities.

AI 分析 of AdaptHealth Corp. (AHCO)

持有

Adapthealth Corp is not a strong buy right now due to significant recent losses and a declining sales forecast. The current price is $6.06, and the stock has a high RSI of 77.713, indicating it may be overbought. Additionally, the forward P/E ratio is 7.776, which suggests it may be undervalued, but the company's recent earnings report showed a loss of $1.07 per share, far below expectations, leading to a 47% drop in stock price. The main risk is the declining cash flow projections, now expected between $80 million and $120 million, down from previous estimates, which could hinder future growth.

估值指标

AdaptHealth Corp.(AHCO)当前预期市盈率为 7.78,5 年平均预期市盈率为 12.46。

预期市盈率

低估
5 年均值 P/E
12.46
当前P/E
7.78
高估
16.86
低估
8.06

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
5.94
当前EV/EBITDA
6.25
高估
7.08
低估
4.80

预期市销率

低估
5 年均值 P/S
0.53
当前P/S
0.28
高估
0.76
低估
0.29

Alphio AI 对 AHCO 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%AHCO

$9.12

情景价格

基

基准

基准 · 50%AHCO

$8.64

情景价格

悲

悲观

悲观 · 25%AHCO

$7.24

情景价格

持有 AHCO 的大户

D

Deerfield Management Company, L.P.

+ 持有AHCO

-6.90%

3个月收益率

事件时间线

2026-09-08 (ET)

16:30:00

AdaptHealth Appoints Harriss T. Currie as CFO

2026-08-04 (ET)

12:00:00

Major Averages Surge Again, Tech Shares Lead Gains

07:30:00

Company Revises FY2026 Financial Guidance to $2.85B-$2.89B

07:30:00

AdaptHealth Reports Q2 Revenue of $740.3M, Lowers Full-Year Outlook

2026-07-20 (ET)

17:00:00

AdaptHealth Divests Diabetes Health Business to Cardinal Health for $235M

资讯

AHCO 常见问题 —— 由 Alphio AI 解答

AdaptHealth Corp. and subsidiaries are engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under three segments that align with its product categories: Sleep Health, Respiratory Health, and Wellness at Home. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea. The Respiratory Health segment provides oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services to individuals for the treatment of respiratory diseases, such as chronic obstructive pulmonary disease and chronic respiratory failure. The Wellness at Home segment provides home medical equipment and services to patients in their homes, including those who have been discharged from acute care and other facilities. It operates in the Healthcare sector (SERVICES-HOME HEALTH CARE SERVICES industry).

Adapthealth Corp is not a strong buy right now due to significant recent losses and a declining sales forecast. The current price is $6.06, and the stock has a high RSI of 77.713, indicating it may be overbought. Additionally, the forward P/E ratio is 7.776, which suggests it may be undervalued, but the company's recent earnings report showed a loss of $1.07 per share, far below expectations, leading to a 47% drop in stock price. The main risk is the declining cash flow projections, now expected between $80 million and $120 million, down from previous estimates, which could hinder future growth.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易